​

Eterna Therapeutics Stock (NASDAQ:ERNA)

RevenueFinancialsChart
Eterna Therapeutics by TradingView

Previous Close

$0.25

52W Range

$0.22 - $2.63

50D Avg

$0.71

200D Avg

$1.57

Market Cap

$12.94M

Avg Vol (3M)

$731.54K

Beta

7.77

Div Yield

-

ERNA Company Profile

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Aug 29, 1991

Website

ERNA Performance

ERNA Financial Summary

Dec 23Dec 22Dec 21
Revenue$68.00K--
Operating Income$-21.14M$-33.22M$68.34M
Net Income$-21.68M$-24.58M$-122.31M
EBITDA$-21.14M$-32.03M$68.80M
Basic EPS$-4.08$-8.06$-56.49
Diluted EPS$-4.08$-8.06$-56.49

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
CGEMCullinan Oncology, Inc.
ZVSAZyVersa Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
RCUSArcus Biosciences, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
RLAYRelay Therapeutics, Inc.
RNAZTransCode Therapeutics, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
TCRXTScan Therapeutics, Inc.
ANNXAnnexon, Inc.
IMMXImmix Biopharma, Inc.
ITOSiTeos Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
GPCRStructure Therapeutics Inc.
ZURAZura Bio Limited
UNCYUnicycive Therapeutics, Inc.
PALIPalisade Bio, Inc.